Michael J Fox has Parkinson’s Disease and I Love You

26.08.10 / parkinson disease / Author: Alex / Comments: (27)
Tags: Disease, love, Michael, parkinsons

The Doctor sings a song about Michael J. Fox, one of his favourite actors of the 1980′s and 90′s. (this song is NOT to be taken seriously!!) Dr. Noise Website: www.drnoise.org Visit his website and help find a cure! http Lyrics: My darlin’ sit down I got something to tell ya there’s good news and bad news and you know they’re both true Michael J. Fox, The Actor we love from back to the future, teen wolf but not teen wolf 2 he’s got a disease and his substancianagra His dopamine receptors aren’t recepting too good now he’s shakin’ around like it’s nobodys business but he’s raising awareness so it can be understood I know I haven’t been around as much as you want me I know that I”m not all that you need but Michael J Fox has put it all in perspective and I want to be the best I can be Michael J fox has put me at ease and I know what I’m feeling is so true Miachel J Fox has parkinson’s disease and I love you My darlin’ don’t cry, there are drugs that can help him Some are many years old some are brand spakin’ new The most common drug it’s name is aldopa its been on the market since 1972 Now I don’t mean to cry there is no cure yet symptoms can be supressed but everyone dies except for Michael J Fox, he’ll beat all the odds Just like Alex P. Keaton did back on Family Ties I want to be your lover and be with you forever I want to hold you as we grow old Watching reruns of spin city together you know that you belong in my soul over 1 million americans have been diagnosed with …
Video Rating: 4 / 5

Parkinson’s Disease – Pipeline Assessment and Market Forecasts to 2016 Report added in Vision Shopsters

The industry analysis specialist’s new report, “Parkinson’s Disease – Pipeline Assessment and Market Forecasts to 2016″ is an essential source of information and analysis on the global Parkinson’s disease market. The report identifies the key trends shaping and driving the global Parkinson’s disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global Parkinson’s disease sector. GlobalData estimated the global Parkinson’s disease market to be valued at ,178m in 2009. It is forecast to grow at 0.9% annually for the next seven years to reach ,384m by 2016. This low growth is ascribed to patent expirations, subsequent entry of generics, weak developmental pipeline and the unknown cause of the disease continues to pose significant challenges for prospective market entrants, is expected to keep the market static. Ageing population would be a key driver of this market. The global Parkinson’s disease market is not well served with current product options and boundless scope is available to new entrants that would capture value from underserved segments. Designing disease-modifying drugs rather than drugs for providing symptomatic relief is one of the key challenges of this market and could provide significant market for any company. GlobalData finds that the global Parkinson’s disease market is increasingly hampered by lack of innovation. On the whole, the late stage pipeline consists of drugs that are aimed at the symptomatic treatment of the disease. There are 181 products in different developmental stages in 2010. Majorly, pipeline presents drugs that are aimed at symptomatic treatment of the disease. Balancing the pipeline with the huge burden of the disease and high expectations of patients, the pipeline is considered to be weak. If a company wants to capture this unmet need, it will need to overcome the prevailing product weaknesses and adverse effects such as dyskinesis, psychiatric side effects and obsessive compulsive behaviors. Currently, these are the biggest challenges preventing most pipeline products from capturing these unmet needs.

Scope

The scope of the report includes:
– Annualized global Parkinson’s disease market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
– Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes dopamine agonists, adenosine receptor antagonists, serotonin receptor targetters, glutamate receptor antagonists, NMDA receptor targetters, AMPA receptor antagonists, stem cell and gene therapy.
– Analysis of the current and future market competition in the global Parkinson’s disease market. Key future market players covered are Merck Serono, Acadia Pharmaceuticals, Axxonis Pharma AG, Avicena Group Inc., and Solvay Pharmaceuticals.
– Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with Parkinson’s disease.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
– Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global Parkinson’s disease market.
– Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global Parkinson’s disease market in future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
– What’s the next big thing in the global Parkinson’s disease market landscape? – Identify, understand and capitalize.

Companies Mentioned

Merck Serono
Acadia Pharmaceuticals
Axxonis Pharma AG
Avicena Group Inc.
Solvay Pharmaceuticals
Impax Laboratories

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/2132/Parkinson-s-Disease-–-Pipeline-Assessment-and-Market-Forecasts-to-2016.html

Contact us:

Visionshopsters
Ph : 91-22-40583000
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

Parkinson’s Disease: A Guide to Patient Care

“As a quick, user-friendly reference, this book covers all aspects of effectively managing patients with Parkinson’s disease, with discussions of symptoms, causes, patient evaluation, and home care advice .Nurses, physicians, and associated healthcare professions from rehabilitation specialists to social workers will find this an excellent source of information on the many aspects of care of Parkinson’s disease patients.” –Doody’s This book serves as a practical compendium on the manageme

Rating: (out of 1 reviews)

List Price: $ 62.00

Price: $ 51.30

Stem cell ruling to be appealed; some work to stop
The Obama administration said Tuesday it will appeal a court ruling that undercut federally funded embryonic stem cell research. But dozens of experiments aimed at fighting spinal cord injuries, Parkinson’s disease and other ailments probably will stop in the meantime.
Read more on Minnesota Public Radio

Question by ♀ BS ♀: What are some things I should know about Parkinson’s Disease?
My dad was diagnosed with Parkinson’s Disease today. Not that I don’t know the basics of it, but I wondered if anyone here has had relatives or friends close to you who’ve been diagnosed with it. What should we expect? Do you have any personal stories you can share about what living with someone with Parkinson’s is like?

Thanks in advance.

Best answer:

Answer by Max Clarkso
My grandmother has it.
It makes her very irritable and that’s pretty much it.
The shaking depends on the severity. She is not too bad and it stops occasionally.
Everything should be okay so don’t worry too much. Good luck!

Know better? Leave your own answer in the comments!

Radiology in Deep Brain Stimulator placement?

07.07.09 / deep brain / Author: Alex / Comments: (1)
Tags: brain, love, perspective, point of view, protocol, rundown, stimulators

I’m writing a paper on the involvement of radiologic technologists in the placment of Deep Brain Stimulators. I’ve found quite a bit of information about the procedure from a surgical point of view and I’ve also located a patient willing to present her perspective… what I need is a complete rundown of the procedures and equipment used by the radiographers imaging during the procedure. Can anyone provide this? If anyone happens to work in a department than has even a protocol for the procedure, I’d love to see it. Thanks!